Published in Hospital Business Week, December 2nd, 2007
As an intervention strategy for viral infection, new approaches for treating RSV include delivering to the respiratory system short interfering ribonucleic acid oligonucleotides (siRNAs), the molecules that induce RNA interference. Quinn will use Aktiv-Dry's proprietary supercritical carbon dioxide process, CAN-BD, to formulate an oligonucleotide...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.